ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,930.85
1.09%
US Tech 100
20,836.00
1.31%
Dow Jones
42,840.26
1.18%
Brent Oil
72.72
0.00%
Bitcoin
97,454.93
-0.31%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Intellia Therapeutics Inc (NTLA) Quote

Intellia Therapeutics Inc

Intellia Therapeutics Inc (NTLA)

NASDAQ
12.18
0.10
(0.83%)
Closed December 21 4:00PM
Delayed by 15 minutes
12.4458
0.2658
(2.18%)
After Hours: 7:57PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
12.4458
Bid
11.68
Ask
12.52
Volume
3,685,823
11.85 Day's Range 12.45
11.79 52 Week Range 34.87
Market Cap
1.268B
Previous Close
12.08
Open
11.94
Last Trade
200
@
12.4458
(formt)
Last Trade Time
Financial Volume
$ 44,886,638
VWAP
12.1782
Average Volume (3m)
2,592,375
Shares Outstanding
101,848,572
Dividend Yield
-
PE Ratio
-2.58
Earnings Per Share (EPS)
-4.72
Revenue
36.28M
Net Profit
-481.19M

About Intellia Therapeutics Inc

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering speci... Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. Show more

Sector
In Vitro,in Vivo Diagnostics
Industry
In Vitro,in Vivo Diagnostics
Website
www.intelliatx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Intellia Therapeutics Inc is listed in the In Vitro,in Vivo Diagnostics sector of the NASDAQ with ticker NTLA. The last closing price for Intellia Therapeutics was $12.08. Over the last year, Intellia Therapeutics shares have traded in a share price range of $ 11.79 to $ 34.87.

Intellia Therapeutics currently has 101,848,572 shares outstanding. The market capitalization of Intellia Therapeutics is $1.23 billion. Intellia Therapeutics has a price to earnings ratio (PE ratio) of -2.58.

Ask ADVFN Intelligence (AI)

Intellia Therapeutics (NTLA) Options Flow Summary

NTLA Options Flow

Overall Flow

Bearish

Net Premium

-63k

Calls / Puts

0.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

NTLA Latest News

More News

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...

December 03 2024
GlobeNewswire Inc.

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

CAMBRIDGE, Mass, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...

November 25 2024
GlobeNewswire Inc.

Form 8-K - Current report

November 18 2024
Edgar (US Regulatory)

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that...

November 16 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 07 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 07 2024
Edgar (US Regulatory)

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on...

November 07 2024
GlobeNewswire Inc.

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...

November 05 2024
GlobeNewswire Inc.

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

Third quarter 2024 financial results – November 7, at 8 a.m. ETNew clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z) for the treatment of transthyretin (ATTR) amyloidosis –...

October 31 2024
GlobeNewswire Inc.

Form 8-K - Current report

October 25 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.0542-7.8088888888913.513.7911.79285369612.65796653CS
4-1.5542-11.10142857141416.0111.79233775114.01749745CS
12-8.5642-40.762494050521.0121.469911.79259237515.74469516CS
26-12.0542-49.200816326524.528.1811.79198750018.68951343CS
52-19.5842-61.143303153332.0334.8711.79175104821.91431863CS
156-114.5042-90.196297755126.95129.2711.79134019037.55021594CS
260-2.7242-17.9578114715.17202.739.18127603350.91499155CS

NTLA - Frequently Asked Questions (FAQ)

What is the current Intellia Therapeutics share price?
The current share price of Intellia Therapeutics is $ 12.4458
How many Intellia Therapeutics shares are in issue?
Intellia Therapeutics has 101,848,572 shares in issue
What is the market cap of Intellia Therapeutics?
The market capitalisation of Intellia Therapeutics is USD 1.23B
What is the 1 year trading range for Intellia Therapeutics share price?
Intellia Therapeutics has traded in the range of $ 11.79 to $ 34.87 during the past year
What is the PE ratio of Intellia Therapeutics?
The price to earnings ratio of Intellia Therapeutics is -2.58
What is the cash to sales ratio of Intellia Therapeutics?
The cash to sales ratio of Intellia Therapeutics is 34.28
What is the reporting currency for Intellia Therapeutics?
Intellia Therapeutics reports financial results in USD
What is the latest annual turnover for Intellia Therapeutics?
The latest annual turnover of Intellia Therapeutics is USD 36.28M
What is the latest annual profit for Intellia Therapeutics?
The latest annual profit of Intellia Therapeutics is USD -481.19M
What is the registered address of Intellia Therapeutics?
The registered address for Intellia Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Intellia Therapeutics website address?
The website address for Intellia Therapeutics is www.intelliatx.com
Which industry sector does Intellia Therapeutics operate in?
Intellia Therapeutics operates in the IN VITRO,IN VIVO DIAGNOSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
$ 4.2001
(211.12%)
120.01M
NVNINVNI Group Ltd
$ 8.26
(209.36%)
76.64M
TPICTPI Composites Inc
$ 2.45
(100.82%)
33.95M
ICGIntchains Group Ltd
$ 8.77
(88.60%)
527.61k
HSDTHelius Medical Technologies Inc
$ 0.884851
(84.34%)
120.4M
CYNCYNGN Inc
$ 0.4603
(-71.41%)
27.91M
MTEMMolecular Templates Inc
$ 0.1502
(-57.09%)
8.75M
PRFXPainReform Ltd
$ 5.15
(-53.85%)
2.94M
GALTGalectin Therapeutics Inc
$ 1.03
(-48.50%)
9.27M
BCABBioAtla Inc
$ 0.6923
(-41.82%)
6.25M
EDBLEdible Garden AG Inc
$ 0.24
(65.06%)
354.32M
APTOAptose Biosciences Inc
$ 0.28
(64.51%)
305.1M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.606999
(6.49%)
292.16M
NVDANVIDIA Corporation
$ 134.70
(3.08%)
287.21M
PLTRPalantir Technologies Inc
$ 80.55
(8.54%)
277.63M

NTLA Discussion

View Posts
PonkenPlonken PonkenPlonken 1 month ago
80mil raised at 25$ per share in q3...
waky waky soon?
👍️0
Monksdream Monksdream 2 months ago
NTLA anew 52 week low
👍️0
PonkenPlonken PonkenPlonken 2 months ago
the trial design desperately needs to be changed. Someone with a serious, progressing and/or life threatening disease does not have the opportunity and right (!) to access a potential cure that often has already been well established in clinical trials, for example a ph1 or ph2.

I would bet many people suffering from HAE would take this NTLA compound ON THE SPOT. Same is true for cancer patients in other instances. Some phase 2 compounds dwarth the standard of care in terms of efficacy and safety ------ But they will have to wait another 3-8 years for the ph3 to finish and the FDA to approve it.

Imagine we would do this with AI or natural resources.....
👍️0
PonkenPlonken PonkenPlonken 2 months ago
violently undervalued
👍️0
jondoeuk jondoeuk 2 months ago
OT: In this Dr. Urnov, PhD, laid out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies https://www.liebertpub.com/doi/10.1089/crispr.2024.0082
👍️0
Monksdream Monksdream 2 months ago
NTLA new 52 week low
👍️0
Monksdream Monksdream 3 months ago
NTLA still trending south
👍️0
Monksdream Monksdream 4 months ago
NTLA that awful Cathie Wood bought more shares
👍️0
Monksdream Monksdream 7 months ago
NTLA was added Friday to Cathie Wood’s ARKK fund
This stock has made a round trip priced back to where it was four years ago
👍️0
jondoeuk jondoeuk 7 months ago
(OT): A new AI paper from Princeton and Stanford https://www.biorxiv.org/content/10.1101/2024.04.25.591003v2.full

CRISPR-GPT demonstrated a marked improvement in gene-editing experiments, increasing the accuracy of target gene modifications by up to 30% compared to conventional methods. In validation tests, it achieved a specificity rate exceeding 95%, with a significant reduction in off-targets. The system also reduced the time required to design and plan experiments by approximately 40%, streamlining the workflow for researchers.
👍️0
Monksdream Monksdream 8 months ago
NTLA new 52 week low
👍️0
jondoeuk jondoeuk 8 months ago
Found it

👍️0
Monksdream Monksdream 8 months ago
NTLA new 52 lo
👍️0
Monksdream Monksdream 8 months ago
NTLA new 52 lo
👍️0
jondoeuk jondoeuk 8 months ago
Is NTLA-3001 over before it even starts? https://crisprmedicinenews.com/news/genome-editing-with-cas9-and-aav-generates-frequent-insertion-of-viral-vectors-that-are-difficult-to/
👍️0
jondoeuk jondoeuk 9 months ago
Slides https://recodetx.com/wp-content/uploads/2024/01/ReCode-Non-Confidential-Overview_Jan-2024.pdf
👍️0
jondoeuk jondoeuk 9 months ago
They are opting out of an agreement with REGN to co-develop a factor IX gene editing therapy for haemophilia A and B. The agreement, which was signed in 2020, will terminate 180 days after NTLA provide written notice to REGN. They will continue to have obligations related to the co-development of gene-editing products directed to factor IX until the effective date of termination. Upon termination, NTLA will no longer be obligated for sharing 35% of the development costs, or be entitled to receive 35% of the profits, for gene-editing products directed to factor IX under the agreement.

Separately, the company would continue to support REGN with the development of gene-editing products directed to factor IX, as applicable, pursuant to a 2016 license and collaboration agreement between the companies. NTLA may be eligible to receive up to $320M in milestone payments and royalties in the high-single digits to low teens if REGN develops and commercialises gene-editing products under the terms of this license and collaboration deal.
👍️0
jondoeuk jondoeuk 10 months ago
I assume (rightly or wrongly) the DNA writer is likely a prime editor https://www.businesswire.com/news/home/20240215392146/en/Intellia-Therapeutics-and-ReCode-Therapeutics-Announce-Strategic-Collaboration-to-Develop-Novel-Gene-Editing-Therapies-for-Cystic-Fibrosis
👍️0
jondoeuk jondoeuk 10 months ago
I'm glad I didn't take a (long) position. I expect an offering soon. CRSP did one, and now PRME. NTLA has not only underperformed, but they are now going to dilute their shareholders more!
👍️0
Monksdream Monksdream 10 months ago
Gene editing companies can be hit and miss

Good research from Nanolyze
👍️0
jondoeuk jondoeuk 12 months ago
Looks like they cleaned almost all of the ex vivo programs. They also pivoted one in vivo program and changed it to DNA based writing. Now, they are pretty much left with 2001, 2002 and 3001. This on top of a 15% cut of the workforce (that extends cash runway into mid-2026). Let's hope there are no hiccups! https://www.globenewswire.com/news-release/2024/01/04/2804303/0/en/Intellia-Therapeutics-Highlights-its-Three-Year-Strategic-Priorities-and-Anticipated-2024-Key-Milestones.html
👍️0
jondoeuk jondoeuk 1 year ago
New preclinical data, but for some reason they won't upload the poster(s) https://jitc.bmj.com/content/11/Suppl_1/A391

They also focused on CD8+ T-cells, but we know CD4+ T-cells are important https://www.sciencedirect.com/science/article/pii/S0952791521001230

For example, in this the authors showed that SOCS1-inactivation improved the intrinsic and extrinsic antitumour effect of adoptively transferred CD4+ T-cells. In addition, inactivation not only restored CD4+ T-cell expansion but it boosted CD8+ T-cell efficacy as well https://www.science.org/doi/10.1126/sciimmunol.abe8219
👍️0
Monksdream Monksdream 1 year ago
NTLA new 52 week low
👍️0
jondoeuk jondoeuk 1 year ago
First time I had heard about Intellia's proprietary Nme2 CRISPR/Cas9 (Nme2Cas9). A quick search brings back the following: ''Nme2Cas9 combines all-in-one AAV compatibility, exceptional editing accuracy within cells, and high target site density for in vivo genome editing applications.'' https://www.cell.com/molecular-cell/fulltext/S1097-2765(18)31033-5
👍️0
jondoeuk jondoeuk 1 year ago
Regeneron Pharmaceuticals and Intellia announced they expanded their existing research collaboration for gene editing therapies to focus on additional targets in neurological and muscular diseases https://finance.yahoo.com/news/regeneron-intellia-announce-expanded-research-110000224.html

The expanded deal combines Regeneron viral vector delivery technologies and Intellia gene modification technologies. Per the terms, the duo will initially research two in vivo non-liver targets, and each company will have the chance to lead potential development and commercialisation for candidates aimed at one target. The company that doesn't lead the program can enter a co-development and co-commercialisation agreement for the target.
👍️0
Monksdream Monksdream 1 year ago
That awful Cathie Wood bought more
Intellia Therapeutics Inc NASDAQ: NTLA

GoSymbol lookup
Health Care : Biotechnology | Small Cap BlendCompany profile
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). It is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned chimeric antigen receptor T (CAR-T) cell candidate, NTLA-6001 targeting CD30 for the treatment of CD30-expressing hematologic cancers, including relapsed or refractory classical Hodgkin's lymphoma.
👍️0
52172 52172 2 years ago
Holding long for 300 plus easy money
👍️0
jondoeuk jondoeuk 3 years ago
New preclinical data https://www.globenewswire.com/news-release/2022/05/02/2433370/0/en/Intellia-Therapeutics-Presents-Preclinical-Data-Demonstrating-Advancements-in-its-CRISPR-Engineered-Allogeneic-Platform-at-the-2022-Keystone-Symposia-s-Precision-Genome-Engineering.html

Slides https://3o5c4w3neipl16yvhj3nfqam-wpengine.netdna-ssl.com/wp-content/uploads/2022-05-01_Schultes_Keystone-2022.pdf
👍️0
jondoeuk jondoeuk 3 years ago
Also, https://jitc.bmj.com/content/8/Suppl_3/A103.2
👍️0
jondoeuk jondoeuk 3 years ago
https://www.fiercebiotech.com/research/engineered-tcr-t-cells-by-fred-hutch-san-raffaele-intellia-fend-off-evasive-leukemia-solid
👍️0
jondoeuk jondoeuk 3 years ago
ASH abstracts

A Novel Strategy for Off-the-Shelf T Cell Therapy Which Evades Allogeneic T Cell and NK Cell Rejection https://ash.confex.com/ash/2021/webprogram/Paper152999.html

Clinical-Scale Production and Characterization of Ntla-5001 - a Novel Approach to Manufacturing CRISPR/Cas9 Engineered T Cell Therapies https://ash.confex.com/ash/2021/webprogram/Paper153775.html
👍️0
jondoeuk jondoeuk 3 years ago
PR https://www.globenewswire.com/news-release/2021/10/20/2317270/0/en/Intellia-Therapeutics-Presents-Preclinical-Data-Demonstrating-Advancements-in-its-Broad-Genome-Editing-Capabilities-at-the-2021-European-Society-of-Gene-Cell-Therapy-Annual-Congres.html

Consecutive Genome Editing in Non Human Primate Achieves Durable Production of Human Alpha-1 Antitrypsin and Reduction of the Native Protein https://3o5c4w3neipl16yvhj3nfqam-wpengine.netdna-ssl.com/wp-content/uploads/AATD-2021-ESGCT-Final.pdf

A Novel Strategy for Off the shelf T Cell Therapies Evading Host T Cell and NK Cell Rejection https://3o5c4w3neipl16yvhj3nfqam-wpengine.netdna-ssl.com/wp-content/uploads/Allo-2021-ESGCT-Final.pdf

Lipid Nanoparticles (LNPs) as a Superior CRISPR/Cas9 Delivery Modality for Highly Efficient Multiplex Gene Editing of T Cells for Adoptive Cell Therapy https://3o5c4w3neipl16yvhj3nfqam-wpengine.netdna-ssl.com/wp-content/uploads/LNP-2021-ESGCT-Final.pdf
👍️0
jondoeuk jondoeuk 3 years ago
The company will present new data at the 29th Annual Congress of the European Society of Gene & Cell Therapy meeting, taking place virtually from October 19-21.

Oral Presentations:

Title: A Novel Strategy for Off-the-shelf T Cell Therapies Evading Host T Cell and NK Cell Rejection
Abstract number: OR18
Date/Time: Wednesday, October 20, 2021, 10:45 a.m. CEST
Location: Session 2c: Immunotherapy for cancer & CAR T cells
Presenting Author: Yong Zhang, Ph.D., associate director, Cell Therapy

Title: Consecutive Genome Editing in Non-Human Primate Achieves Durable Production of Human Alpha-1 Antitrypsin at Physiologic Levels and Reduction of the Homologous Native Protein
Abstract number: OR12
Date/Time: Wednesday, October 20, 2021, 10:15 a.m. CEST
Location: Session 2b: Gene editing I
Presenting Author: Sean Burns, M.D., vice president of Intellia’s Disease Biology and Pharmacology group

Invited Talk:
Title: Advances in CRISPR/Cas9 Therapeutic Genome Editing for In Vivo and Ex Vivo Applications
Date/Time: Friday, October 22, 2021, 11:30 a.m. CEST
Location: Session 7b: Liver and metabolic diseases II
Presenting Author: Laura Sepp-Lorenzino. Ph.D., chief scientific officer

Poster Presentation:
Title: Lipid Nanoparticles (LNPs) as a Superior CRISPR/Cas9 Delivery Modality for Highly Efficient Multiplex Gene Editing of T Cells for Adoptive Cell Therapy
Abstract number: P205
Date/Time: Tuesday, October 19, 2021, 8:00 a.m. CEST
Presenting Author: Aaron Prodeus, Ph.D., principal scientist, Cell Therapy
👍️0
jondoeuk jondoeuk 3 years ago
The company has announced that it has submitted its first CTA to the UK's MHRA for NTLA-5001 (an auto TCR-T cell therapy targeting WT1) to initiate a PhI trial. The company expects to initiate screening by year-end. This first-in-human trial is expected to evaluate the safety and activity in patients with persistent or recurrent AML who have previously received first-line therapies.

Also, last month they submitted an application to the New Zealand's MMDS to begin a PhI trial for NTLA-2002. Additional applications with other countries are following. It utilises the company's modular in vivo lipid nanoparticle delivery technology to knock out the KLKB1 gene in the liver with the potential to permanently reduce plasma kallikrein protein and activity, a key mediator of HAE.
👍️0
Glider549 Glider549 3 years ago
And BEAM
👍️0
Gpheart2016 Gpheart2016 3 years ago
Sudden burst in genomic stocks. NTLA, EDIT, CRSP moving together. What happened?
👍️0
make it happen make it happen 3 years ago
Big gap and lot of money to be spent on continuation of just for hope. Hope everything comes to fruition in the long but like you said it a ways away.
👍️0
go_glortho go_glortho 3 years ago
You do understand that this is a biotech startup that does not yet generate revenue yet? They have a pipeline of products that aren't set to make it to the market until at least next year? They've proven that the CRISPR-Cas9 technology can be effective - now it's time to finish the clinicals and get approval from the FDA to market the products. Geez!!
👍️0
make it happen make it happen 3 years ago
Large negatives across the board. Revenue Per Share $0.86

Profitability
Profit Margin -288.47%
Operating Margin (ttm) -291.05%

Management Effectiveness
Return on Assets (ttm) -18.17%
Return on Equity (ttm) -37.46%

Income Statement
Revenue (ttm) 51.52M
Revenue Per Share (ttm) 0.86
Quarterly Revenue Growth (yoy) -50.10%
Gross Profit (ttm) -92.41M
EBITDA -143.6M
Net Income Avi to Common (ttm) -148.63M
Diluted EPS (ttm) -2.47

Balance Sheet
Total Cash (mrq) 584.06M
Total Cash Per Share (mrq) 8.57
Total Debt (mrq) 72.74M
Total Debt/Equity (mrq) 13.33
Current Ratio (mrq) 9.90
Book Value Per Share (mrq) 8.04

Cash Flow Statement
Operating Cash Flow (ttm) -63.74M
Levered Free Cash Flow (ttm) -45.03M
👍️0
jondoeuk jondoeuk 3 years ago
Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics have teamed to create a CAR-T therapy start-up https://ir.intelliatx.com/static-files/fca9b71d-739f-4d79-863d-f1c4dc27bcf1
👍️0
jondoeuk jondoeuk 4 years ago
Adding CD8 coreceptors may enhance CD4+ T-cell responses (for MHC Class I-restricted antigens) by stabilising TCR-pMHC interactions. Also, it serves to enhance avidity from low affinity TCRs, while enhancing activation https://www.tandfonline.com/doi/full/10.4161/onci.22590

Another way would be to target MHC Class II-restricted antigens https://www.jci.org/articles/view/120391
👍️0
jondoeuk jondoeuk 4 years ago
Knock-ins, knockdowns and/or overexpression are other ways to improve activity. For example, in this, knockdown enhanced CD8+ and CD4+ T-cell accumulation in the tumour, increased proliferation and increased cytokine production https://www.nature.com/articles/nature12988
👍️0
jondoeuk jondoeuk 4 years ago
In the setting of established and (rapidly) proliferating disease, there is a need to enhance and sustain T-cell function, activity, and persistence. However, too many inhibitory and not enough costimulatory signals are a major hurdle. But one way to overcome this is with immunomodulatory fusion proteins, such as this https://ashpublications.org/blood/article/130/22/2410/36564/A-CD200R-CD28-fusion-protein-appropriates-an

So I hope the company explore it.
👍️0
jondoeuk jondoeuk 4 years ago
This was presented at SITC last year https://jitc.bmj.com/content/8/Suppl_3/A103.2
👍️0
jondoeuk jondoeuk 4 years ago
This trial showed that donor-derived, CD8+ T-cells engineered (using a viral vector) to express a WT1 TCR could prevent relapse of patients at high risk (post HCT) [1].

Based on it, a PhI/II trial is ongoing testing central memory vs. naive CD8+ T-cells for the treatment of high-risk AML patients post-induction chemo (over 80% will relapse within the first year [2]). As of Dec '19, seven had been treated. Four are NED (one out to over 500 days), one relapsed (but declined further treatment), and two had overt disease (one due to WT1 negative leukaemia cells).

I think the product (5001) produced by NTLA should show even better results due to a number of factors.

Refs:
1 https://www.nature.com/articles/s41591-019-0472-9
2 https://ascopubs.org/doi/full/10.1200/JCO.2014.58.3518
👍️0
jondoeuk jondoeuk 4 years ago
https://www.businesswire.com/news/home/20210107005234/en/ArsenalBio-Announces-Multi-Program-Discovery-Collaboration-with-Bristol-Myers-Squibb-to-Advance-Next-Generation-T-cell-Therapies-for-Solid-Tumors
👍️0
Fress Fress 4 years ago
Cathie Wood likes some cutting edge Gene editing stocks including NTLA.



Genome Stocks-Gene Editing.
$BEAM 5 billion market cap ARKG ETF
$EDIT 5.1 billion market cap ARKG ETF
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap ARK ETF
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders ARKG ETF


$NTLA
👍️0
jondoeuk jondoeuk 4 years ago
NTLA 5001, a T Cell Product Candidate with CRISPR Based Targeted Insertion of a High Avidity, Natural, WT1 Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL https://3o5c4w3neipl16yvhj3nfqam-wpengine.netdna-ssl.com/wp-content/uploads/Intellia-ASH-Poster-Presentation_12.05.2020.pdf
👍️0
jondoeuk jondoeuk 4 years ago
Arsenal Bio [1] is also using it for screening [2] and editing [3]. Different TCRs and CARs [4] will be used for solid tumours, and they are working on ways to overcome exhaustion [5].

Refs:
1 https://www.businesswire.com/news/home/20191017005246/en/ArsenalBio-Launches-With-85-Million-Series-A-Financing-to-Advance-New-Paradigm-to-Discover-and-Develop-Immune-Cell-Therapies
2 https://www.sciencedirect.com/science/article/abs/pii/S0092867420303329
3 https://www.nature.com/articles/s41587-019-0325-6
4 https://www.globenewswire.com/news-release/2020/10/21/2111794/0/en/Teneobio-Announces-a-Research-Collaboration-and-License-Agreement-With-ArsenalBio.html
5 https://www.nature.com/articles/s41586-019-1325-x
👍️0
jondoeuk jondoeuk 4 years ago
Currently, the company is using CRISPR/Cas9 screening to identify edits that can improve infiltration, expansion, potency, and persistence, while also prevent exhaustion of T-cells. Using T-cells with these properties should help in their development of more effective TCR-T cell therapies in a range of solid tumours. They identified both known and novel regulators, and importantly, a number of knock-out targets that accumulate in multiple, distinct TMEs and other targets that are specific.

Data from other groups have shown that deletion of a ribonuclease augmented the capacity of T-cells to control tumour growth by enhancing their ability to infiltrate and persist within the TME [1]. Similarly, a knockout of a transcription factor lead to the improvement in the cytolytic properties of T-cells [2].

They could go further and use TCRs that target both MHC Class-I and II antigens [3], along with delivering 'payloads' to modulate TMEs [4-9].

Refs:
1 https://www.nature.com/articles/s41586-019-1821-z
2 https://www.cell.com/cell/fulltext/S0092-8674(16)31149-7
3 https://www.jci.org/articles/view/120391
4 https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30101-1
5 https://www.nature.com/articles/s41590-020-0676-7
6 https://cancerimmunolres.aacrjournals.org/content/8/6/743
7 https://cancerimmunolres.aacrjournals.org/content/8/4/518
8 https://cancerres.aacrjournals.org/content/71/17/5697.long
9 https://www.jci.org/articles/view/58814
👍️0

Your Recent History

NASDAQ
NTLA
Intellia Therapeutics
BIT
NSCIT00120N2
Kingdom of Spain
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads